New findings from a phase 3 randomized withdrawal trial suggest that continued treatment with ecopipam (Emalex Biosciences), an investigational dopamine D1 receptor antagonist, significantly reduces the risk of symptom relapse in children and…
Ecopipam Maintains Efficacy and Reduces Relapse Risk in Phase 3 Trial in Tourette Syndrome | NeurologyLive
